Use of Calcium Channel Blockers and Parkinson%26apos;s Disease

作者：Pasternak Bjorn^*; Svanstrom Henrik; Nielsen Nete M; Fugger Lars; Melbye Mads; Hviid Anders

来源：American Journal of Epidemiology, 2012, 175(7): 627-635.

DOI：10.1093/aje/kwr362

• antihypertensive agents
• calcium channel blockers
• neurology
• Parkinson%26apos
• s disease

Experimental evidence and case-control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Parkinson%26apos;s disease. The authors conducted a historical cohort study in Denmark to investigate the association between DiCCB use and risk of Parkinson%26apos;s disease (1998-2006). Individual-level data on filled drug prescriptions, diagnostic information, and covariates were linked between nationwide registries. Among DiCCB users, 173 incident cases of Parkinson%26apos;s disease were detected during 461,984 person-years of follow-up, compared with 5,538 cases during 17,343,641 person-years of follow-up among nonusers. After adjustment for age, sex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associated with a reduced risk of Parkinson%26apos;s disease (rate ratio (RR) = 0.71, 95% confidence interval (CI): 0.60, 0.82). This association was not present in patients who had previously used DiCCBs (RR = 1.04, 95% CI: 0.87, 1.24). DiCCB users aged %26gt;= 65 years were at lower risk of Parkinson%26apos;s disease than DiCCB users aged %26lt;65 years (RR = 0.59, 95% CI: 0.40, 0.85). Among patients with Parkinson%26apos;s disease, DiCCB use was associated with reduced risk of death (adjusted RR = 0.66, 95% CI: 0.47, 0.91) but not dementia (adjusted RR = 0.97, 95% CI: 0.60, 1.56). In conclusion, DiCCB exposure was associated with a reduced risk of incident Parkinson%26apos;s disease, particularly in older patients, and with reduced mortality among patients with Parkinson%26apos;s disease.

• 出版日期2012-4-1